HLA antibody screening: comparison of a solid phase enzyme-linked immunoassay with antiglobulin-augmented lymphocytotoxicity.
BACKGROUND
IgG antibodies to HLA class I antigens can cause hyperacute rejection of renal allografts. Screening of sera from such transplant candidates is laborious, time-consuming, and expensive when performed by sensitive antihuman globulin-augmented lymphocytotoxicity (AHG-CDC).


METHODS
Because 60-70% of our transplant screens are negative, we evaluated a solid phase enzyme-linked method (EIA) as a potential prescreen by parallel testing 215 sera by AHG-CDC and by EIA. This EIA method is designed to detect only IgG antibodies, and all positive AHG-CDC sera were retested after dithiothreitol treatment.


RESULTS
There was 96.2% concordance between the tests for IgG antibodies. Seven sera (3.25%) were positive by EIA alone, and one (0.46%) was negative by EIA alone. The EIA method was also less costly ($15.00 versus $105.00) and less time consuming (hours versus days) than AHG-CDC panel testing for large numbers of sera.


CONCLUSIONS
We conclude that this EIA method is simple, sensitive, objective, and cost effective as a prescreen for HLA class I antibodies.
Moore
S B
SB
Histocompatibility Laboratory, Division of Transfusion Medicine, Mayo Clinic, Mayo Foundation, Rochester, Minnesota 55905, USA.
Ploeger
N A
NA
DeGoey
S R
SR
D003601:Cytotoxicity Tests, Immunologic / Q000191:economics / Q000379:methods*; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D007124:Immunoenzyme Techniques / Q000191:economics; D007074:Immunoglobulin G / Q000032:analysis; D014181:Transplantation Immunology
D015395:Histocompatibility Antigens Class I; D007074:Immunoglobulin G